The Ministry of Health has published on Friday the reports on the decision to finance 18 new medicines, mostly approved since October 2024 after a positive opinion of the Interministerial Commission of Price of Medicines, and which aims to “strengthen” the transparency of the incorporation of therapeutic innovations to the National Health System.
“Transparency in this process is essential to generate confidence and allow health professionals and patients to make informed decisions. Reports offer a detailed vision of each new medication included in the pharmaceutical provision,” said healing in a statement.
What information include reports
Each report includes the basic information of each medication, which provides the most relevant of the active substance, as well as its therapeutic indications, dosage and other aspects. The texts describe the evaluation and authorization process of each medication by the European Medicines Agency or the Spanish Agency for Medicines and Health Products.
Similarly, information about the CIPM decision is included in relation to the financing of the medication. In addition, they detail the conditions of inclusion of the medication in the National Health System, such as information on the population to which it is destined or possible restrictions, among others.
These documents also refer to the resolution issued by the General Directorate of SNS and Pharmacy Services portfolio, which formalizes the inclusion of the medication in the pharmaceutical provision.
The drugs included in the report
Los Informs Publicados Se Corpsponden with Los Fármacos Cerliponasa Alfa (‘Toasto’), Factor VIII de la coagulación (‘altuvoct’), lomitapida (‘lojuxt’), cefepima_enmetazobactam (‘Exblifep’), aztreonam_avibactam (‘Emblaveo’), Rezafungina (‘Rezzayo’), Dafrafenib (‘Finlee’), Trametinib (‘Spexotras’), Fruquintinib (‘Fruzaqla’), Quizartinib (‘Vanflyta’), TisliLizumab (‘Tevimbra’), Epcoritamab (‘Tepkinly’), TalquetaMab, (‘Talvey’), Talazoparib (‘Talzenna’), RozanoLixizumab (‘Rystiggo’), Dantroleno (‘Agilus’), Desflurano (‘Desflurano Baxter’) y Gadopiclenol (‘Elucirem’).
